Carregant...
Update on the role of nanoliposomal irinotecan in the treatment of metastatic pancreatic cancer
Median survival for patients with metastatic pancreatic cancer (MPC) treated with combination chemotherapeutic agents such as gemcitabine-based regimens and FOLFIRINOX is currently less than 12 months. This highlights the need for more efficacious first-line, as well as second-line therapies. Nanoli...
Guardat en:
| Publicat a: | Therap Adv Gastroenterol |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publications
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5484436/ https://ncbi.nlm.nih.gov/pubmed/28804517 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756283X17705328 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|